Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Joaquim Bosch-Barrera

Professor Associat Doctor

Universitat de Girona

Spain

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Pharmacotherapy

50%

Pharmacology

40%

Oncology

70%

Tyrosine Kinase

40%

Neoadjuvant Therapy

30%

Lung Disease

30%

Cancer Biology

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles20

Biomarker landscape in advanced NSCLC: insights from a national prospective registry

Article Link

Year:

2025

Incidence of second primary cancers in lung cancer survivors by oncological treatment: a nationwide prospective cohort study in Spain

Article Link

Year:

2025

Mitochondrial priming and response to BH3 mimetics in “one-two punch” senogenic-senolytic strategies

Article Link

Year:

2025

ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer

Article Link

Year:

2025

Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry

Article Link

Year:

2024

Lung cancer survival trends and prognostic factors: A 26-year population-based study in Girona Province, Spain

Article Link

Year:

2024

Fatty acid synthase (FASN) is a tumor-cell-intrinsic metabolic checkpoint restricting T-cell immunity

Article Link

Year:

2024

STAR-121: A Phase III Randomized Study of Domvanalimab and Zimberelimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Untreated Metastatic Non-Small Cell Lung Cancer With No Actionable Gene Alterations.

Article Link

Year:

2024

Immunogenicity of COVID-19 vaccines in lung cancer patients.

Article Link

Year:

2023

Machine Learning-Assisted Recurrence Prediction for Patients With Early-Stage Non-Small-Cell Lung Cancer.

Article Link

Year:

2023

Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.

Article Link

Year:

2023

Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.

Article Link

Year:

2023

Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients

Article Link

Year:

2023

Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional study

Article Link

Year:

2023

Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells

Article Link

Year:

2022

Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors

Article Link

Year:

2022

AZ12756122, a novel fatty acid synthase inhibitor, decreases resistance features in EGFR-TKI resistant EGFR-mutated NSCLC cell models.

Article Link

Year:

2022

Molecular Divergence upon <i>EGFR</i>-TKI Resistance Could Be Dependent on the Exon Location of the Original <i>EGFR</i>-Sensitizing Mutation

Article Link

Year:

2022

Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics.

Article Link

Year:

2022

Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations

Article Link

Year:

2022

Collaborators14

Jorge Joven

Professor

Universitat Rovira i Virgili

SPAIN

Delvys Rodriguez-Abreu

Universidad de Las Palmas de Gran Canaria

SPAIN

Florentino Hernando-Trancho. MD/PhD/Prof

Instituto de Investigación Sanitaria del Hospital Clínico San Carlos

SPAIN

ATOCHA ROMERO

Associate Professor

Universidad CEU San Pablo

SPAIN

Boris Duchemann

FRANCE

Pedro Sousa

Universidade de Aveiro

PORTUGAL

Antonio Segura-Carretero

Universidad de Granada

SPAIN

Joao Pimentao

Professor Auxiliar

Faculdade de Ciências da Universidade de Lisboa

PORTUGAL

Andrea De Giglio

University of Bologna

ITALY

Mariano Provencio Pulla

Head of Medical Oncology Department at Puerta de Hierro University Hospital

Hospital Universitario Puerta del Hierro Majadahonda

SPAIN

José Antonio Encinar

Profesor Titular de Universidad

Universidad Miguel Hernández de Elche

SPAIN

Javier De Castro

HEAD OF LUNG CANCER UNIT

La Paz University Hospital

SPAIN

Jose Carlos Benitez

Instituto de Investigación Biomédica de Málaga

SPAIN

jose m lizcano

Universitat Autònoma de Barcelona (UAB)

SPAIN

How do I reach out?

Meet Kite AI